OMX Nordic 40
|
2 617,28
|
15,82
|
0,61 %
|
Analysen zu OMX Nordic 40-Werten
| 29.01.26 | ABB Neutral | JP Morgan Chase & Co. | |
| 29.01.26 | Nokia Overweight | JP Morgan Chase & Co. | |
| 29.01.26 | Nokia Neutral | UBS AG | |
| 29.01.26 | Hennes & Mauritz AB Hold | Jefferies & Company Inc. | |
| 29.01.26 | ABB Hold | Jefferies & Company Inc. | |
| 29.01.26 | Nokia Buy | Jefferies & Company Inc. | |
| 29.01.26 | Volvo AB Overweight | JP Morgan Chase & Co. | |
| 28.01.26 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 28.01.26 | Volvo AB Buy | Jefferies & Company Inc. | |
| 28.01.26 | Volvo AB Outperform | RBC Capital Markets | |
| 28.01.26 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
| 28.01.26 | AstraZeneca Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 27.01.26 | Nokia Overweight | JP Morgan Chase & Co. | |
| 26.01.26 | Volvo AB Buy | Jefferies & Company Inc. | |
| 26.01.26 | Hennes & Mauritz AB Sector Perform | RBC Capital Markets | |
| 23.01.26 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 23.01.26 | Ericsson Underperform | Bernstein Research | |
| 23.01.26 | Ericsson Sell | UBS AG | |
| 23.01.26 | Novo Nordisk Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 22.01.26 | A.P. Moeller - Maersk A-S Underweight | JP Morgan Chase & Co. | |
| 22.01.26 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 22.01.26 | Novo Nordisk Equal Weight | Barclays Capital | |
| 22.01.26 | Volvo AB Market-Perform | Bernstein Research | |
| 21.01.26 | Novo Nordisk Neutral | UBS AG | |
| 21.01.26 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 20.01.26 | Volvo AB Buy | UBS AG | |
| 20.01.26 | ABB Neutral | UBS AG | |
| 20.01.26 | Novo Nordisk Neutral | UBS AG | |
| 20.01.26 | Nokia Overweight | JP Morgan Chase & Co. | |
| 16.01.26 | Novo Nordisk Buy | Deutsche Bank AG | |
| 16.01.26 | AstraZeneca Buy | UBS AG | |
| 16.01.26 | AstraZeneca Sell | Deutsche Bank AG | |
| 16.01.26 | Novo Nordisk Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 15.01.26 | AstraZeneca Overweight | Barclays Capital | |
| 15.01.26 | Novo Nordisk Equal Weight | Barclays Capital | |
| 15.01.26 | Nokia Overweight | Morgan Stanley | |
| 15.01.26 | Novo Nordisk Neutral | UBS AG | |
| 15.01.26 | ABB Market-Perform | Bernstein Research | |
| 15.01.26 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 15.01.26 | Novo Nordisk Overweight | JP Morgan Chase & Co. |